| Field | Row 1 |
|---|---|
| adsh | 0001792044-25-000018 |
| cik | 1792044 |
| name | VIATRIS INC |
| sic | 2834 |
| countryba | US |
| stprba | PA |
| cityba | CANONSBURG |
| zipba | 15317 |
| bas1 | 1000 MYLAN BOULEVARD |
| bas2 | |
| baph | (724) 514-1465 |
| countryma | US |
| stprma | PA |
| cityma | CANONSBURG |
| zipma | 15317 |
| mas1 | 1000 MYLAN BOULEVARD |
| mas2 | |
| countryinc | US |
| stprinc | DE |
| ein | 834364296 |
| former | UPJOHN INC |
| changed | 20191023 |
| afs | 1-LAF |
| wksi | 0 |
| fye | 1231 |
| form | 10-Q |
| period | 20250331 |
| fy | 2025 |
| fp | Q1 |
| filed | 20250508 |
| accepted | 2025-05-08 09:21:00.0 |
| prevrpt | 0 |
| detail | 1 |
| instance | vtrs-20250331_htm.xml |
| nciks | 1 |
| aciks |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| cik | Central Index Key (CIK). Ten digit number assigned by the SEC to each registrant that submits filings. |
| name | Name of registrant. This corresponds to the name of the legal entity as recorded in EDGAR as of the filing date. |
| sic | Standard Industrial Classification (SIC). Four digit code assigned by the SEC as of the filing date, indicating the registrant’s type of business. |
| countryba | The ISO 3166-1 country of the registrant's business address. |
| stprba | The state or province of the registrant’s business address, if field countryba is US or CA. |
| cityba | The city of the registrant's business address. |
| zipba | The zip code of the registrant’s business address. |
| bas1 | The first line of the street of the registrant’s business address. |
| bas2 | The second line of the street of the registrant’s business address. |
| baph | The phone number of the registrant’s business address. |
| countryma | The ISO 3166-1 country of the registrant's mailing address. |
| stprma | The state or province of the registrant’s mailing address, if field countryma is US or CA. |
| cityma | The city of the registrant's mailing address. |
| zipma | The zip code of the registrant’s mailing address. |
| mas1 | The first line of the street of the registrant’s mailing address. |
| mas2 | The second line of the street of the registrant’s mailing address. |
| countryinc | The ISO 3166-1 country of incorporation for the registrant. |
| stprinc | The state or province of incorporation for the registrant, if countryinc is US or CA. |
| ein | Employee Identification Number, 9 digit identification number assigned by the Internal Revenue Service to business entities operating in the United States. |
| former | Most recent former name of the registrant, if any. |
| changed | Date of change from the former name, if any. |
| afs | Filer status with the SEC at the time of submission: 1-LAF=Large Accelerated, 2-ACC=Accelerated, 3-SRA=Smaller Reporting Accelerated, 4-NON=Non-Accelerated, 5-SML=Smaller Reporting Filer, NULL=not assigned. |
| wksi | Well Known Seasoned Issuer (WKSI). An issuer that meets specific SEC requirements at some point during a 60-day period preceding the date the issuer satisfies its obligation to update its shelf registration statement. |
| fye | Fiscal Year End Date, rounded to nearest month-end. |
| form | The submission type of the registrant’s filing. |
| period | Balance Sheet Date, rounded to nearest month-end. |
| fy | Fiscal Year Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8). |
| fp | Fiscal Period Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8) within Fiscal Year. |
| filed | The date of the registrant’s filing with the Commission. |
| accepted | The acceptance date and time of the registrant’s filing with the Commission. |
| prevrpt | Previous Report – TRUE indicates that the submission information was subsequently amended. |
| detail | TRUE indicates that the XBRL submission contains quantitative disclosures within the footnotes and schedules at the required detail level (e.g., each amount). |
| instance | The name of the submitted XBRL Instance Document. The name often begins with the company ticker symbol. |
| nciks | Number of Central Index Keys (CIK) of registrants (i.e., business units) included in the consolidating entity’s submitted filing. |
| aciks | Additional CIKs of co-registrants included in a consolidating entity’s EDGAR submission, separated by spaces. If there are no other co-registrants (i.e., nciks=1), the value of aciks is NULL. For a very small number of filers, the entire list of co-registrants is too long to fit in the field. Where this is the case, users should refer to the complete submission file for all CIK information. |
| adsh | ddate | tag | value | uom | qtrs | version | segments | coreg | footnote |
|---|---|---|---|---|---|---|---|---|---|
| 0001792044-25-000018 | 20250331 | Accrued Income Taxes Current | 93400000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | 20200000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Changeinnoncashlitigationsettlementsnet | -80300000.0000 | USD | 1 | 0001792044-25-000018 | |||
| 0001792044-25-000018 | 20241231 | Deferred Income Tax Assets Net | 753000000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Dividends Common Stock Cash | 146100000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20241231 | Goodwill | 6752900000.0000 | USD | 0 | us-gaap/2025 | Business Segments= Developed Markets Segment; | ||
| 0001792044-25-000018 | 20240331 | Goodwill Impairment Loss | 0.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Income Tax Expense Benefit | -55000000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Increase Decrease In Other Operating Capital Net | 111800000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20241231 | Long Term Debt Noncurrent | 749300000.0000 | USD | 0 | us-gaap/2025 | Debt Instrument= A2028 Senior Notes; Longterm Debt Type= Senior Notes; | ||
| 0001792044-25-000018 | 20240331 | Operating Income Loss | 203900000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax | 600000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Other Research And Development Expense Refund | 10000000.0000 | USD | 1 | 0001792044-25-000018 | |||
| 0001792044-25-000018 | 20240331 | Payments For Proceeds From Other Investing Activities | 1000000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250430 | Payments For Repurchase Of Common Stock | 139500000.0000 | USD | 0 | us-gaap/2025 | Subsequent Event Type= Subsequent Event; | ||
| 0001792044-25-000018 | 20250331 | Payments To Minority Shareholders | 143300000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20241231 | Prepaid Expense And Other Assets Current | 1710500000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Proceeds From Sale Of Productive Assets | 11300000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20241231 | Property Plant And Equipment Net | 2666100000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Research And Development Expense | 199700000.0000 | USD | 1 | us-gaap/2025 | Consolidation Items= Material Reconciling Items; | ||
| 0001792044-25-000018 | 20250331 | Research And Development Expense | 222000000.0000 | USD | 1 | us-gaap/2025 | Consolidation Items= Material Reconciling Items; | ||
| 0001792044-25-000018 | 20240331 | Restricted Stock Value Shares Issued Net Of Tax Withholdings | 6700000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Restricted Stock Value Shares Issued Net Of Tax Withholdings | 14000000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Additional Paid In Capital; | ||
| 0001792044-25-000018 | 20250331 | Retained Earnings Accumulated Deficit | 227900000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 626400000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Emerging Markets Segment; Consolidation Items= Operating Segments; | ||
| 0001792044-25-000018 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 184100000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Japan Australia And New Zealand Segment; Product Or Service= Brands; | ||
| 0001792044-25-000018 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 1344400000.0000 | USD | 1 | us-gaap/2025 | Product Or Service= Generics; | ||
| 0001792044-25-000018 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 388000000.0000 | USD | 1 | us-gaap/2025 | Product Or Service= Lipitor; | ||
| 0001792044-25-000018 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 37100000.0000 | USD | 1 | us-gaap/2025 | Product Or Service= Xalabrands; | ||
| 0001792044-25-000018 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 32300000.0000 | USD | 1 | us-gaap/2025 | Product Or Service= Xanax; | ||
| 0001792044-25-000018 | 20240331 | Revenue Not From Contract With Customer | 2400000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Emerging Markets Segment; Product Or Service= Product And Service Other; | ||
| 0001792044-25-000018 | 20240331 | Share Based Compensation | 46700000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -3212900000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001792044-25-000018 | 20250331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 18960800000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Additional Paid In Capital; | ||
| 0001792044-25-000018 | 20241231 | Stockholders Equity Parent Before Treasury Stock | 19139800000.0000 | USD | 0 | 0001792044-25-000018 | |||
| 0001792044-25-000018 | 20240331 | Stock Issued During Period Value New Issues | 600000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Stock Issued During Period Value New Issues | 600000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Additional Paid In Capital; | ||
| 0001792044-25-000018 | 20240331 | Stock Issued During Period Value Stock Options Exercised Net Of Shares Tendered For Payment | 8842107.0000 | shares | 1 | 0001792044-25-000018 | Equity Components= Common Stock; | ||
| 0001792044-25-000018 | 20250331 | Treasury Stock Shares Acquired | 18600000.0000 | shares | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Treasury Stock Value Acquired Cost Method | 175500000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Treasury Stock Common; | ||
| 0001792044-25-000018 | 20241231 | Assets Current | 9520700000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 756300000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Changeinnoncashlitigationsettlementsnet | 69400000.0000 | USD | 1 | 0001792044-25-000018 | |||
| 0001792044-25-000018 | 20240331 | Common Stock Dividends Per Share Cash Paid | 0.1200 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20241231 | Common Stock Value | 12300000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Cost Of Goods And Services Sold | 2093100000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Dividends Common Stock Cash | 146100000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Retained Earnings; | ||
| 0001792044-25-000018 | 20250331 | Dividends Common Stock Cash | 148900000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 16800000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Gain Loss Related To Litigation Settlement | 73500000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Goodwill Impairment Loss | 375000000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Emerging Markets Segment; | ||
| 0001792044-25-000018 | 20240331 | Income Tax Expense Benefit | 90700000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Increase Decrease In Accounts Payable Trade | 101600000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Increase Decrease In Accrued Income Taxes Payable | -2300000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20241231 | Liabilities Current | 5779400000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20241231 | Long Term Debt Noncurrent | 999900000.0000 | USD | 0 | us-gaap/2025 | Debt Instrument= Senior Notes Two Thousand Forty Six5.25 Precent; Longterm Debt Type= Senior Notes; | ||
| 0001792044-25-000018 | 20250331 | Net Income Loss Available To Common Stockholders Basic | -3042000000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Operating Expenses | 1300100000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Operating Income Loss | -2882200000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20241231 | Other Assets Noncurrent | 2356900000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Other Comprehensive Income Loss Before Tax Portion Attributable To Parent | -27500000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Accumulated Gain Loss Net Cash Flow Hedge Parent; | ||
| 0001792044-25-000018 | 20240331 | Other Comprehensive Income Loss Tax | 42400000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Other Liabilities Current | 3629800000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Payments Of Merger Related Costs Financing Activities | 10900000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Proceeds From Repayments Of Short Term Debt | 1400000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 72200000.0000 | USD | 1 | us-gaap/2025 | Product Or Service= Celebrex; | ||
| 0001792044-25-000018 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 176300000.0000 | USD | 1 | us-gaap/2025 | Product Or Service= Norvasc; | ||
| 0001792044-25-000018 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 871900000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Developed Markets Segment; Product Or Service= Generics; | ||
| 0001792044-25-000018 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 555500000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Greater China Segment; Consolidation Items= Operating Segments; | ||
| 0001792044-25-000018 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 96700000.0000 | USD | 1 | us-gaap/2025 | Product Or Service= Epi Pen Auto Injectors; | ||
| 0001792044-25-000018 | 20240331 | Revenue Not From Contract With Customer | 9900000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Revenue Not From Contract With Customer | 7200000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Developed Markets Segment; Product Or Service= Product And Service Other; | ||
| 0001792044-25-000018 | 20250331 | Revenue Not From Contract With Customer | 11100000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Revenues | 628800000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Emerging Markets Segment; | ||
| 0001792044-25-000018 | 20240331 | Revenues | 318100000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Japan Australia And New Zealand Segment; | ||
| 0001792044-25-000018 | 20240331 | Shares Issued | 1230891074.0000 | shares | 0 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0001792044-25-000018 | 20250331 | Stock Issued During Period Shares New Issues | 62491.0000 | shares | 1 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0001792044-25-000018 | 20241231 | Treasury Stock Common Shares | 40483663.0000 | shares | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Weighted Average Number Of Diluted Shares Outstanding | 1192400000.0000 | shares | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Accounts Receivable Net Current | 3125700000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Assets Current | 9622400000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20241231 | Cash And Cash Equivalents At Carrying Value | 734800000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Common Stock Value | 12400000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Deferred Income Tax Assets Net | 817600000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Deferred Income Tax Expense Benefit | -43600000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Depreciation Depletion And Amortization | 664700000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Earnings Per Share Basic | 0.1000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Earnings Per Share Diluted | -2.5500 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Goodwill Impairment Loss | 2936800000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Goodwill Impairment Loss | -1554000000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Europe Segment; | ||
| 0001792044-25-000018 | 20240331 | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | 204600000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Increase Decrease In Accounts Receivable | -168000000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Increase Decrease In Accrued Income Taxes Payable | -120600000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Increase Decrease In Inventories | 193700000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Intangible Assets Net Excluding Goodwill | 16662300000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20241231 | Liabilities And Stockholders Equity | 41500900000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Long Term Debt Noncurrent | 497600000.0000 | USD | 0 | us-gaap/2025 | Debt Instrument= Senior Notes Two Thousand Forty Three; Longterm Debt Type= Senior Notes; | ||
| 0001792044-25-000018 | 20250331 | Net Cash Provided By Used In Investing Activities | -65100000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Net Income Loss Available To Common Stockholders Basic | 113900000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Operating Expenses | 4043400000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Operating Income Loss | 87300000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Japan Australia And New Zealand Segment; Consolidation Items= Operating Segments; | ||
| 0001792044-25-000018 | 20250331 | Operating Income Loss | 738100000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Developed Markets Segment; Consolidation Items= Operating Segments; | ||
| 0001792044-25-000018 | 20240331 | Other Comprehensive Income Loss Before Tax Portion Attributable To Parent | -151200000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Other Comprehensive Income Loss Before Tax Portion Attributable To Parent | -342500000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Accumulated Translation Adjustment; | ||
| 0001792044-25-000018 | 20250331 | Other Comprehensive Income Loss Before Tax Portion Attributable To Parent | 498800000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Accumulated Translation Adjustment; | ||
| 0001792044-25-000018 | 20250331 | Other Comprehensive Income Loss Before Tax Portion Attributable To Parent | -173700000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Aoci Derivative Qualifying As Hedge Excluded Component Parent; | ||
| 0001792044-25-000018 | 20250331 | Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Before Tax | -173700000.0000 | USD | 1 | us-gaap/2025 | Derivative Instruments Gain Loss By Hedging Relationship= Net Investment Hedging; | ||
| 0001792044-25-000018 | 20240331 | Other Comprehensive Income Loss Net Of Tax | -193600000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001792044-25-000018 | 20250331 | Other Comprehensive Income Loss Net Of Tax | 342000000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001792044-25-000018 | 20250331 | Other Comprehensive Income Loss Tax | -44000000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20241231 | Other Liabilities Noncurrent | 1939200000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Other Nonoperating Income Expense | 139100000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Payments For Repurchase Of Common Stock | 175400000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Payments Related To Tax Withholding For Share Based Compensation | 29300000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Payments To Acquire Businesses Net Of Cash Acquired | 350000000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Payments To Acquire In Process Research And Development Other | 5200000.0000 | USD | 1 | 0001792044-25-000018 | |||
| 0001792044-25-000018 | 20250331 | Prepaid Expense And Other Assets Current | 1645300000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Proceeds From Issuance Of Common Stock | 600000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Proceeds From Payments For Other Financing Activities | 6200000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Research And Development Expense | 199700000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Research And Development Expense | 222000000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Restricted Stock Value Shares Issued Net Of Tax Withholdings | 6600000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Additional Paid In Capital; | ||
| 0001792044-25-000018 | 20250331 | Restricted Stock Value Shares Issued Net Of Tax Withholdings | 100000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0001792044-25-000018 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 80200000.0000 | USD | 1 | us-gaap/2025 | Product Or Service= Epi Pen Auto Injectors; | ||
| 0001792044-25-000018 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 402500000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Emerging Markets Segment; Product Or Service= Brands; | ||
| 0001792044-25-000018 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 552800000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Greater China Segment; Product Or Service= Brands; | ||
| 0001792044-25-000018 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 2700000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Greater China Segment; Product Or Service= Generics; | ||
| 0001792044-25-000018 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 134300000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Japan Australia And New Zealand Segment; Product Or Service= Generics; | ||
| 0001792044-25-000018 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 33300000.0000 | USD | 1 | us-gaap/2025 | Product Or Service= Amitiza; | ||
| 0001792044-25-000018 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 58300000.0000 | USD | 1 | us-gaap/2025 | Product Or Service= Yupelri; | ||
| 0001792044-25-000018 | 20250331 | Revenue Not From Contract With Customer | 0.0000 | USD | 1 | us-gaap/2025 | Business Segments= Greater China Segment; Product Or Service= Product And Service Other; | ||
| 0001792044-25-000018 | 20240331 | Revenues | 543900000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Greater China Segment; | ||
| 0001792044-25-000018 | 20250331 | Revenues | 1898600000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Developed Markets Segment; | ||
| 0001792044-25-000018 | 20241231 | Shares Issued | 1234131491.0000 | shares | 0 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0001792044-25-000018 | 20240331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 12300000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0001792044-25-000018 | 20250331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -2870900000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001792044-25-000018 | 20250331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 12400000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0001792044-25-000018 | 20250331 | Treasury Stock Shares Acquired | 18607602.0000 | shares | 1 | us-gaap/2025 | Equity Components= Treasury Stock Common; | ||
| 0001792044-25-000018 | 20231231 | Treasury Stock Value | 251800000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20241231 | Treasury Stock Value | 504300000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Weighted Average Number Of Diluted Shares Outstanding | 1209500000.0000 | shares | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20241231 | Long Term Debt Current | 8300000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20241231 | Accounts Receivable Net Current | 3221300000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20241231 | Accounts Receivable Net Current | 2536400000.0000 | USD | 0 | us-gaap/2025 | Accounts Notes Loans And Financing Receivable By Receivable Type= Variable Consideration; | ||
| 0001792044-25-000018 | 20250331 | Accounts Receivable Net Current | 2516700000.0000 | USD | 0 | us-gaap/2025 | Accounts Notes Loans And Financing Receivable By Receivable Type= Variable Consideration; | ||
| 0001792044-25-000018 | 20241231 | Assets | 41500900000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Assets | 38474900000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20231231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 993600000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | 22300000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20241231 | Common Stock Shares Authorized | 3000000000.0000 | shares | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Comprehensive Income Net Of Tax | -79700000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Earnings Per Share Basic | -2.5500 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Gain Loss On Sale Of Business | 70400000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Gross Profit | 1161200000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20230331 | Income Tax Expense Benefit | 22300000.0000 | USD | 0 | us-gaap/2025 | Income Tax Authority= Foreign Country; Income Tax Authority Name= Ministry Of Finance India; | ||
| 0001792044-25-000018 | 20250331 | Interest Expense | 115500000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20241231 | Inventory Net | 3854100000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Inventory Net | 4096400000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20241231 | Long Term Debt Noncurrent | 747900000.0000 | USD | 0 | us-gaap/2025 | Debt Instrument= A2048 Senior Notes; Longterm Debt Type= Senior Notes; | ||
| 0001792044-25-000018 | 20241231 | Long Term Debt Noncurrent | 2200000.0000 | USD | 0 | us-gaap/2025 | Debt Instrument= Other Long Term Debt; | ||
| 0001792044-25-000018 | 20240331 | Net Cash Provided By Used In Financing Activities | -425600000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Operating Income Loss | 1421000000.0000 | USD | 1 | us-gaap/2025 | Consolidation Items= Operating Segments; | ||
| 0001792044-25-000018 | 20240331 | Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax | -300000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Other Comprehensive Income Loss Net Of Tax | -193600000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Tax | 200000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Other Nonoperating Income Expense | 13400000.0000 | USD | 1 | us-gaap/2025 | Disposal Group Classification= O T C Business; | ||
| 0001792044-25-000018 | 20240331 | Other Research And Development Expense Refund | 6100000.0000 | USD | 1 | 0001792044-25-000018 | |||
| 0001792044-25-000018 | 20250331 | Payments Of Merger Related Costs Financing Activities | 11400000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Payments To Acquire Property Plant And Equipment | 42600000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Proceeds From Sale And Maturity Of Marketable Securities | 4600000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 1178800000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Developed Markets Segment; Product Or Service= Brands; | ||
| 0001792044-25-000018 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 100700000.0000 | USD | 1 | us-gaap/2025 | Product Or Service= Viagra; | ||
| 0001792044-25-000018 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 1019800000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Developed Markets Segment; Product Or Service= Brands; | ||
| 0001792044-25-000018 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 519900000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Emerging Markets Segment; Consolidation Items= Operating Segments; | ||
| 0001792044-25-000018 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 2116900000.0000 | USD | 1 | us-gaap/2025 | Product Or Service= Brands; | ||
| 0001792044-25-000018 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 82400000.0000 | USD | 1 | us-gaap/2025 | Product Or Service= Creon; | ||
| 0001792044-25-000018 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 60200000.0000 | USD | 1 | us-gaap/2025 | Product Or Service= Zoloft; | ||
| 0001792044-25-000018 | 20250331 | Revenue Not From Contract With Customer | 6900000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Developed Markets Segment; Product Or Service= Product And Service Other; | ||
| 0001792044-25-000018 | 20250331 | Share Based Compensation | 55200000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 20014300000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 227900000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Retained Earnings; | ||
| 0001792044-25-000018 | 20250331 | Stock Issued During Period Value New Issues | 600000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Stock Issued During Period Value New Issues | 600000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Additional Paid In Capital; | ||
| 0001792044-25-000018 | 20231231 | Treasury Stock Common Shares | 21239521.0000 | shares | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Treasury Stock Value Acquired Cost Method | 252500000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20241231 | Accrued Income Taxes Current | 192700000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20241231 | Additional Paid In Capital | 18921600000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 55200000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Additional Paid In Capital; | ||
| 0001792044-25-000018 | 20250331 | Common Stock Dividends Per Share Cash Paid | 0.1200 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20241231 | Deferred Income Tax Liabilities Net | 1107900000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Dividends Common Stock Cash | 148900000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Retained Earnings; | ||
| 0001792044-25-000018 | 20250331 | Gain Loss On Sale Of Business | -36900000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Gain Loss On Sale Of Business | 36900000.0000 | USD | 1 | us-gaap/2025 | Disposal Group Classification= Disposal Group Held For Sale Or Disposed Of By Sale Not Discontinued Operations; Income Statement Location= Other Nonoperating Income Expense; | ||
| 0001792044-25-000018 | 20250331 | Goodwill | 923300000.0000 | USD | 0 | us-gaap/2025 | Business Segments= Greater China Segment; | ||
| 0001792044-25-000018 | 20250331 | Goodwill Impairment Loss | 2261000000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Developed Markets Segment; | ||
| 0001792044-25-000018 | 20250331 | Goodwill Impairment Loss | -707000000.0000 | USD | 1 | us-gaap/2025 | Business Segments= North America Segment; | ||
| 0001792044-25-000018 | 20250331 | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -3097000000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Increase Decrease In Other Operating Capital Net | 177200000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Long Term Debt Noncurrent | 14177500000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Long Term Debt Noncurrent | 1673200000.0000 | USD | 0 | us-gaap/2025 | Debt Instrument= Senior Notes Two Thousand Twenty Six3.95 Precent; Longterm Debt Type= Senior Notes; | ||
| 0001792044-25-000018 | 20250331 | Accounts Payable Trade Current | 1988400000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20241231 | Accumulated Other Comprehensive Income Loss Net Of Tax | -3212900000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Adjustments Related To Tax Withholding For Share Based Compensation | 28800000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Adjustments Related To Tax Withholding For Share Based Compensation | 28800000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Additional Paid In Capital; | ||
| 0001792044-25-000018 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 46700000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20241231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 736100000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Deferred Income Tax Expense Benefit | -51900000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Depreciation Depletion And Amortization | 691000000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Earnings Per Share Diluted | 0.0900 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20241231 | Goodwill | 921500000.0000 | USD | 0 | us-gaap/2025 | Business Segments= Greater China Segment; | ||
| 0001792044-25-000018 | 20241231 | Goodwill | 295100000.0000 | USD | 0 | us-gaap/2025 | Business Segments= Japan Australia And New Zealand Segment; | ||
| 0001792044-25-000018 | 20250331 | Goodwill | 6462100000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Goodwill Impairment Loss | 300800000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Japan Australia And New Zealand Segment; | ||
| 0001792044-25-000018 | 20240331 | Increase Decrease In Accounts Payable Trade | 287900000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Increase Decrease In Accounts Receivable | -9800000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Increase Decrease In Inventories | 370400000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20241231 | Intangible Assets Net Excluding Goodwill | 17070900000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Interest Expense | 138400000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Long Term Debt Current | 8500000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20241231 | Long Term Debt Noncurrent | 14038900000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20241231 | Long Term Debt Noncurrent | 497500000.0000 | USD | 0 | us-gaap/2025 | Debt Instrument= Senior Notes Two Thousand Forty Three; Longterm Debt Type= Senior Notes; | ||
| 0001792044-25-000018 | 20250331 | Long Term Debt Noncurrent | 749300000.0000 | USD | 0 | us-gaap/2025 | Debt Instrument= A2028 Senior Notes; Longterm Debt Type= Senior Notes; | ||
| 0001792044-25-000018 | 20250331 | Long Term Debt Noncurrent | 999900000.0000 | USD | 0 | us-gaap/2025 | Debt Instrument= Senior Notes Two Thousand Forty Six5.25 Precent; Longterm Debt Type= Senior Notes; | ||
| 0001792044-25-000018 | 20240331 | Net Cash Provided By Used In Operating Activities | 614600000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Net Cash Provided By Used In Operating Activities | 535500000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Operating Income Loss | 913300000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Developed Markets Segment; Consolidation Items= Operating Segments; | ||
| 0001792044-25-000018 | 20250331 | Operating Income Loss | 384700000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Greater China Segment; Consolidation Items= Operating Segments; | ||
| 0001792044-25-000018 | 20250331 | Other Assets Noncurrent | 2274900000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Other Comprehensive Income Loss Before Tax Portion Attributable To Parent | -6200000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Accumulated Defined Benefit Plans Adjustment; | ||
| 0001792044-25-000018 | 20250331 | Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Before Tax | -27500000.0000 | USD | 1 | us-gaap/2025 | Derivative Instruments Gain Loss By Hedging Relationship= Cash Flow Hedging; | ||
| 0001792044-25-000018 | 20241231 | Other Liabilities Current | 3724700000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Other Liabilities Noncurrent | 1844400000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Other Noncash Income Expense | -203800000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Proceeds From Divestiture Of Businesses | 240600000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Proceeds From Issuance Of Common Stock | 600000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Proceeds From Payments For Other Financing Activities | -109600000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Proceeds From Refund Of In Process Research And Development | -15000000.0000 | USD | 1 | 0001792044-25-000018 | |||
| 0001792044-25-000018 | 20240331 | Proceeds From Repayments Of Short Term Debt | 0.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Restricted Stock Value Shares Issued Net Of Tax Withholdings | 100000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0001792044-25-000018 | 20241231 | Retained Earnings Accumulated Deficit | 3418800000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 404400000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Emerging Markets Segment; Product Or Service= Brands; | ||
| 0001792044-25-000018 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 133700000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Japan Australia And New Zealand Segment; Product Or Service= Generics; | ||
| 0001792044-25-000018 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 48200000.0000 | USD | 1 | us-gaap/2025 | Product Or Service= Dymista; | ||
| 0001792044-25-000018 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 42500000.0000 | USD | 1 | us-gaap/2025 | Product Or Service= Xalabrands; | ||
| 0001792044-25-000018 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 55200000.0000 | USD | 1 | us-gaap/2025 | Product Or Service= Yupelri; | ||
| 0001792044-25-000018 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 1126300000.0000 | USD | 1 | us-gaap/2025 | Product Or Service= Generics; | ||
| 0001792044-25-000018 | 20240331 | Revenue Not From Contract With Customer | 0.0000 | USD | 1 | us-gaap/2025 | Business Segments= Greater China Segment; Product Or Service= Product And Service Other; | ||
| 0001792044-25-000018 | 20240331 | Revenues | 2172600000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Developed Markets Segment; | ||
| 0001792044-25-000018 | 20250331 | Revenues | 555500000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Greater China Segment; | ||
| 0001792044-25-000018 | 20240331 | Selling General And Administrative Expense | 1017500000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Selling General And Administrative Expense | 948100000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Shares Issued | 1244908128.0000 | shares | 0 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0001792044-25-000018 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 18814700000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Additional Paid In Capital; | ||
| 0001792044-25-000018 | 20240331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -2941000000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001792044-25-000018 | 20240331 | Treasury Stock Shares Acquired | 19200000.0000 | shares | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Treasury Stock Shares Acquired | 19244142.0000 | shares | 1 | us-gaap/2025 | Equity Components= Treasury Stock Common; | ||
| 0001792044-25-000018 | 20250430 | Treasury Stock Shares Acquired | 16400000.0000 | shares | 0 | us-gaap/2025 | Subsequent Event Type= Subsequent Event; | ||
| 0001792044-25-000018 | 20240331 | Net Cash Provided By Used In Investing Activities | -154300000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Operating Income Loss | 279500000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Emerging Markets Segment; Consolidation Items= Operating Segments; | ||
| 0001792044-25-000018 | 20240331 | Operating Income Loss | 366300000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Greater China Segment; Consolidation Items= Operating Segments; | ||
| 0001792044-25-000018 | 20240331 | Operating Income Loss | 1646400000.0000 | USD | 1 | us-gaap/2025 | Consolidation Items= Operating Segments; | ||
| 0001792044-25-000018 | 20240331 | Other Comprehensive Income Loss Before Tax Portion Attributable To Parent | 169100000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Aoci Derivative Qualifying As Hedge Excluded Component Parent; | ||
| 0001792044-25-000018 | 20250331 | Other Comprehensive Income Loss Before Tax Portion Attributable To Parent | 298000000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Before Tax | 28700000.0000 | USD | 1 | us-gaap/2025 | Derivative Instruments Gain Loss By Hedging Relationship= Cash Flow Hedging; | ||
| 0001792044-25-000018 | 20240331 | Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax | -342500000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Other Noncash Income Expense | 3000000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Payments For Proceeds From Other Investing Activities | 18800000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Payments To Acquire Property Plant And Equipment | 49800000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Proceeds From Refund Of In Process Research And Development | 5200000.0000 | USD | 1 | 0001792044-25-000018 | |||
| 0001792044-25-000018 | 20250331 | Property Plant And Equipment Net | 2635600000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 222000000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Emerging Markets Segment; Product Or Service= Generics; | ||
| 0001792044-25-000018 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 543900000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Greater China Segment; Consolidation Items= Operating Segments; | ||
| 0001792044-25-000018 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 2309100000.0000 | USD | 1 | us-gaap/2025 | Product Or Service= Brands; | ||
| 0001792044-25-000018 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 59400000.0000 | USD | 1 | us-gaap/2025 | Product Or Service= Effexor; | ||
| 0001792044-25-000018 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 3243200000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 59300000.0000 | USD | 1 | us-gaap/2025 | Product Or Service= Effexor; | ||
| 0001792044-25-000018 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 112600000.0000 | USD | 1 | us-gaap/2025 | Product Or Service= Lyrica; | ||
| 0001792044-25-000018 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -2747400000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001792044-25-000018 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 12200000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0001792044-25-000018 | 20240331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 4607500000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Retained Earnings; | ||
| 0001792044-25-000018 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 18921600000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Additional Paid In Capital; | ||
| 0001792044-25-000018 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 12300000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0001792044-25-000018 | 20250331 | Stockholders Equity Parent Before Treasury Stock | 16330200000.0000 | USD | 0 | 0001792044-25-000018 | |||
| 0001792044-25-000018 | 20250331 | Weighted Average Number Of Shares Outstanding Basic | 1192400000.0000 | shares | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20241231 | Liabilities | 22865400000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Accumulated Other Comprehensive Income Loss Net Of Tax | -2870900000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Adjustments Related To Tax Withholding For Share Based Compensation | 30600000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Cash And Cash Equivalents At Carrying Value | 1014600000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | -12400000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Gain Loss Related To Litigation Settlement | -76800000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Gain Loss Related To Litigation Settlement | -76800000.0000 | USD | 1 | us-gaap/2025 | Consolidation Items= Material Reconciling Items; | ||
| 0001792044-25-000018 | 20241231 | Goodwill | 9133300000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20241231 | Goodwill | 1163800000.0000 | USD | 0 | us-gaap/2025 | Business Segments= Emerging Markets Segment; | ||
| 0001792044-25-000018 | 20250331 | Goodwill | 4742200000.0000 | USD | 0 | us-gaap/2025 | Business Segments= Developed Markets Segment; | ||
| 0001792044-25-000018 | 20240331 | Gross Profit | 1504000000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Liabilities And Stockholders Equity | 38474900000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20241231 | Long Term Debt Noncurrent | 773700000.0000 | USD | 0 | us-gaap/2025 | Debt Instrument= A2028 Euro Senior Notes; Longterm Debt Type= Senior Notes; | ||
| 0001792044-25-000018 | 20241231 | Long Term Debt Noncurrent | 1672800000.0000 | USD | 0 | us-gaap/2025 | Debt Instrument= Senior Notes Two Thousand Twenty Six3.95 Precent; Longterm Debt Type= Senior Notes; | ||
| 0001792044-25-000018 | 20250331 | Long Term Debt Noncurrent | 747900000.0000 | USD | 0 | us-gaap/2025 | Debt Instrument= A2048 Senior Notes; Longterm Debt Type= Senior Notes; | ||
| 0001792044-25-000018 | 20250331 | Long Term Debt Noncurrent | 2200000.0000 | USD | 0 | us-gaap/2025 | Debt Instrument= Other Long Term Debt; | ||
| 0001792044-25-000018 | 20250331 | Net Cash Provided By Used In Financing Activities | -467000000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Operating Income Loss | 62200000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Japan Australia And New Zealand Segment; Consolidation Items= Operating Segments; | ||
| 0001792044-25-000018 | 20240331 | Other Comprehensive Income Loss Before Tax Portion Attributable To Parent | 28700000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Accumulated Gain Loss Net Cash Flow Hedge Parent; | ||
| 0001792044-25-000018 | 20250331 | Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax | 498800000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Other Comprehensive Income Loss Net Of Tax | 342000000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Other Nonoperating Income Expense | -99300000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Payments To Acquire Marketable Securities | 7700000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Proceeds From Divestiture Of Businesses | 0.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Proceeds From Sale And Maturity Of Marketable Securities | 7700000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Proceeds From Sale Of Productive Assets | 700000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Restricted Stock Value Shares Issued Net Of Tax Withholdings | 14100000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 3653500000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 2165400000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Developed Markets Segment; Consolidation Items= Operating Segments; | ||
| 0001792044-25-000018 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 2100000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Greater China Segment; Product Or Service= Generics; | ||
| 0001792044-25-000018 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 317800000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Japan Australia And New Zealand Segment; Consolidation Items= Operating Segments; | ||
| 0001792044-25-000018 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 114200000.0000 | USD | 1 | us-gaap/2025 | Product Or Service= Lyrica; | ||
| 0001792044-25-000018 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 34500000.0000 | USD | 1 | us-gaap/2025 | Product Or Service= Xanax; | ||
| 0001792044-25-000018 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 58000000.0000 | USD | 1 | us-gaap/2025 | Product Or Service= Zoloft; | ||
| 0001792044-25-000018 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 42800000.0000 | USD | 1 | us-gaap/2025 | Product Or Service= Dymista; | ||
| 0001792044-25-000018 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 172300000.0000 | USD | 1 | us-gaap/2025 | Product Or Service= Norvasc; | ||
| 0001792044-25-000018 | 20231231 | Shares Issued | 1221994491.0000 | shares | 0 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0001792044-25-000018 | 20240331 | Revenue Not From Contract With Customer | 300000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Japan Australia And New Zealand Segment; Product Or Service= Product And Service Other; | ||
| 0001792044-25-000018 | 20250331 | Revenue Not From Contract With Customer | 3200000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Emerging Markets Segment; Product Or Service= Product And Service Other; | ||
| 0001792044-25-000018 | 20250331 | Revenue Not From Contract With Customer | 1000000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Japan Australia And New Zealand Segment; Product Or Service= Product And Service Other; | ||
| 0001792044-25-000018 | 20240331 | Revenues | 3663400000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Revenues | 523100000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Emerging Markets Segment; | ||
| 0001792044-25-000018 | 20250331 | Revenues | 277100000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Japan Australia And New Zealand Segment; | ||
| 0001792044-25-000018 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 20467400000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 4639700000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Retained Earnings; | ||
| 0001792044-25-000018 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 18635500000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 15650400000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Stock Issued During Period Shares New Issues | 54476.0000 | shares | 1 | us-gaap/2025 | Equity Components= Common Stock; | ||
| 0001792044-25-000018 | 20250331 | Stock Issued During Period Value Stock Options Exercised Net Of Shares Tendered For Payment | 10714146.0000 | shares | 1 | 0001792044-25-000018 | Equity Components= Common Stock; | ||
| 0001792044-25-000018 | 20250331 | Treasury Stock Value Acquired Cost Method | 175500000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Weighted Average Number Of Shares Outstanding Basic | 1195200000.0000 | shares | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20241231 | Accounts Payable Trade Current | 1853700000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Additional Paid In Capital | 18960800000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Adjustments Related To Tax Withholding For Share Based Compensation | 30600000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Additional Paid In Capital; | ||
| 0001792044-25-000018 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 46700000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Additional Paid In Capital; | ||
| 0001792044-25-000018 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 55200000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Cash And Cash Equivalents At Carrying Value | 755000000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 1015900000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Comprehensive Income Net Of Tax | -2700000000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Cost Of Goods And Services Sold | 2159400000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Deferred Income Tax Liabilities Net | 1082500000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Gain Loss Related To Litigation Settlement | 73500000.0000 | USD | 1 | us-gaap/2025 | Consolidation Items= Material Reconciling Items; | ||
| 0001792044-25-000018 | 20240229 | Goodwill | 19500000.0000 | USD | 0 | us-gaap/2025 | Business Acquisition= Idorsia Pharmaceuticals Ltd.; | ||
| 0001792044-25-000018 | 20250331 | Goodwill | 796600000.0000 | USD | 0 | us-gaap/2025 | Business Segments= Emerging Markets Segment; | ||
| 0001792044-25-000018 | 20250331 | Goodwill | 0.0000 | USD | 0 | us-gaap/2025 | Business Segments= Japan Australia And New Zealand Segment; | ||
| 0001792044-25-000018 | 20250331 | Goodwill Impairment Loss | 0.0000 | USD | 1 | us-gaap/2025 | Business Segments= Greater China Segment; | ||
| 0001792044-25-000018 | 20250331 | Liabilities | 22824500000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Liabilities Current | 5720100000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Long Term Debt Noncurrent | 808400000.0000 | USD | 0 | us-gaap/2025 | Debt Instrument= A2028 Euro Senior Notes; Longterm Debt Type= Senior Notes; | ||
| 0001792044-25-000018 | 20250331 | Operating Income Loss | 236000000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Emerging Markets Segment; Consolidation Items= Operating Segments; | ||
| 0001792044-25-000018 | 20240331 | Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Before Tax | 169100000.0000 | USD | 1 | us-gaap/2025 | Derivative Instruments Gain Loss By Hedging Relationship= Net Investment Hedging; | ||
| 0001792044-25-000018 | 20240331 | Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Tax | 6200000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Other Nonoperating Income Expense | 17400000.0000 | USD | 1 | us-gaap/2025 | Disposal Group Classification= O T C Business; | ||
| 0001792044-25-000018 | 20240331 | Payments For Repurchase Of Common Stock | 250000000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Payments Related To Tax Withholding For Share Based Compensation | 28700000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Payments To Acquire Businesses Net Of Cash Acquired | 0.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Payments To Acquire In Process Research And Development Other | -15000000.0000 | USD | 1 | 0001792044-25-000018 | |||
| 0001792044-25-000018 | 20250331 | Payments To Acquire Marketable Securities | 4600000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Payments To Minority Shareholders | 142800000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 986600000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Developed Markets Segment; Product Or Service= Generics; | ||
| 0001792044-25-000018 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 541800000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Greater China Segment; Product Or Service= Brands; | ||
| 0001792044-25-000018 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 33000000.0000 | USD | 1 | us-gaap/2025 | Product Or Service= Amitiza; | ||
| 0001792044-25-000018 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 75000000.0000 | USD | 1 | us-gaap/2025 | Product Or Service= Creon; | ||
| 0001792044-25-000018 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 388900000.0000 | USD | 1 | us-gaap/2025 | Product Or Service= Lipitor; | ||
| 0001792044-25-000018 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 1891700000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Developed Markets Segment; Consolidation Items= Operating Segments; | ||
| 0001792044-25-000018 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 117400000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Emerging Markets Segment; Product Or Service= Generics; | ||
| 0001792044-25-000018 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 276100000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Japan Australia And New Zealand Segment; Consolidation Items= Operating Segments; | ||
| 0001792044-25-000018 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 141800000.0000 | USD | 1 | us-gaap/2025 | Business Segments= Japan Australia And New Zealand Segment; Product Or Service= Brands; | ||
| 0001792044-25-000018 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 63400000.0000 | USD | 1 | us-gaap/2025 | Product Or Service= Celebrex; | ||
| 0001792044-25-000018 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 98500000.0000 | USD | 1 | us-gaap/2025 | Product Or Service= Viagra; | ||
| 0001792044-25-000018 | 20250331 | Revenues | 3254300000.0000 | USD | 1 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 18839800000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Additional Paid In Capital; | ||
| 0001792044-25-000018 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 3418800000.0000 | USD | 0 | us-gaap/2025 | Equity Components= Retained Earnings; | ||
| 0001792044-25-000018 | 20240331 | Treasury Stock Common Shares | 40483663.0000 | shares | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Treasury Stock Common Shares | 59091265.0000 | shares | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Treasury Stock Value | 504300000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20250331 | Treasury Stock Value | 679800000.0000 | USD | 0 | us-gaap/2025 | |||
| 0001792044-25-000018 | 20240331 | Treasury Stock Value Acquired Cost Method | 252500000.0000 | USD | 1 | us-gaap/2025 | Equity Components= Treasury Stock Common; |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| ddate | The end date for the data value, rounded to the nearest month end. |
| qtrs | The count of the number of quarters represented by the data value, rounded to the nearest whole number. “0” indicates it is a point-in-time value. |
| uom | The unit of measure for the value. |
| segments | Tags used to represent axis and member reporting. |
| coreg | If specified, indicates a specific co-registrant, the parent company, or other entity (e.g., guarantor). NULL indicates the consolidated entity. |
| value | The value. This is not scaled, it is as found in the Interactive Data file, but is limited to four digits to the right of the decimal point. |
| footnote | The text of any superscripted footnotes on the value, as shown on the statement page, truncated to 512 characters, or if there is no footnote, then this field will be blank. |
| tag | version | custom | abstract | datatype | iord | crdr | tlabel | doc |
|---|---|---|---|---|---|---|---|---|
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2025 | 0 | 0 | monetary | D | D | Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation | Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate. |
| Deferred Income Tax Assets Net | us-gaap/2025 | 0 | 0 | monetary | I | D | Deferred Income Tax Assets, Net | Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting. |
| Net Cash Provided By Used In Investing Activities | us-gaap/2025 | 0 | 0 | monetary | D | D | Cash Provided by (Used in) Investing Activity, Including Discontinued Operation | Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets. |
| Cash And Cash Equivalents At Carrying Value | us-gaap/2025 | 0 | 0 | monetary | I | D | Cash and Cash Equivalent | Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate. |
| Common Stock Shares Authorized | us-gaap/2025 | 0 | 0 | shares | I | Common Stock, Shares Authorized | The maximum number of common shares permitted to be issued by an entity's charter and bylaws. | |
| Earnings Per Share Diluted | us-gaap/2025 | 0 | 0 | perShare | D | Earnings Per Share, Diluted | The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. | |
| Payments To Acquire In Process Research And Development Other | 0001792044-25-000018 | 1 | 0 | monetary | D | C | Payments To Acquire In Process Research And Development, Other | Payments To Acquire In Process Research And Development, Other |
| Other Liabilities Current | us-gaap/2025 | 0 | 0 | monetary | I | C | Other Liabilities, Current | Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer. |
| Proceeds From Issuance Of Common Stock | us-gaap/2025 | 0 | 0 | monetary | D | D | Proceeds from Issuance of Common Stock | The cash inflow from the additional capital contribution to the entity. |
| Property Plant And Equipment Net | us-gaap/2025 | 0 | 0 | monetary | I | D | Property, Plant and Equipment, Net | Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2025 | 0 | 0 | monetary | D | D | Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation | Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate. |
| Accounts Payable Trade Current | us-gaap/2025 | 0 | 0 | monetary | I | C | Accounts Payable, Trade, Current | Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Revenue From Contract With Customer Excluding Assessed Tax | us-gaap/2025 | 0 | 0 | monetary | D | C | Revenue from Contract with Customer, Excluding Assessed Tax | Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | us-gaap/2025 | 0 | 0 | monetary | D | C | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. |
| Selling General And Administrative Expense | us-gaap/2025 | 0 | 0 | monetary | D | D | Selling, General and Administrative Expense | The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. |
| Additional Paid In Capital | us-gaap/2025 | 0 | 0 | monetary | I | C | Additional Paid in Capital | Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. |
| Payments Related To Tax Withholding For Share Based Compensation | us-gaap/2025 | 0 | 0 | monetary | D | C | Payment, Tax Withholding, Share-Based Payment Arrangement | Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement. |
| Stock Issued During Period Value Stock Options Exercised Net Of Shares Tendered For Payment | 0001792044-25-000018 | 1 | 0 | shares | D | Stock Issued During Period, Value, Stock Options Exercised, Net of Shares Tendered for Payment | Stock Issued During Period, Value, Stock Options Exercised, Net of Shares Tendered for Payment | |
| Depreciation Depletion And Amortization | us-gaap/2025 | 0 | 0 | monetary | D | D | Depreciation, Depletion and Amortization | The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. |
| Comprehensive Income Net Of Tax | us-gaap/2025 | 0 | 0 | monetary | D | C | Comprehensive Income (Loss), Net of Tax, Attributable to Parent | Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. |
| Accrued Income Taxes Current | us-gaap/2025 | 0 | 0 | monetary | I | C | Accrued Income Taxes, Current | Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations. |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | us-gaap/2025 | 0 | 0 | monetary | D | C | APIC, Share-Based Payment Arrangement, Increase for Cost Recognition | Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. |
| Deferred Income Tax Liabilities Net | us-gaap/2025 | 0 | 0 | monetary | I | C | Deferred Income Tax Liabilities, Net | Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting. |
| Earnings Per Share Basic | us-gaap/2025 | 0 | 0 | perShare | D | Earnings Per Share, Basic | The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. | |
| Goodwill Impairment Loss | us-gaap/2025 | 0 | 0 | monetary | D | D | Goodwill, Impairment Loss | Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. |
| Increase Decrease In Other Operating Capital Net | us-gaap/2025 | 0 | 0 | monetary | D | C | Increase (Decrease) in Other Operating Assets and Liabilities, Net | Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other. |
| Intangible Assets Net Excluding Goodwill | us-gaap/2025 | 0 | 0 | monetary | I | D | Intangible Assets, Net (Excluding Goodwill) | Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. |
| Long Term Debt Current | us-gaap/2025 | 0 | 0 | monetary | I | C | Long-Term Debt, Current Maturities | Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation. |
| Long Term Debt Noncurrent | us-gaap/2025 | 0 | 0 | monetary | I | C | Long-Term Debt, Excluding Current Maturities | Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. |
| Operating Expenses | us-gaap/2025 | 0 | 0 | monetary | D | D | Operating Expenses | Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. |
| Other Comprehensive Income Loss Before Tax Portion Attributable To Parent | us-gaap/2025 | 0 | 0 | monetary | D | C | Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent | Amount before tax of other comprehensive income (loss) attributable to parent entity. |
| Other Comprehensive Income Loss Tax | us-gaap/2025 | 0 | 0 | monetary | D | D | Other Comprehensive Income (Loss), Tax | Amount of tax expense (benefit) allocated to other comprehensive income (loss). |
| Payments For Repurchase Of Common Stock | us-gaap/2025 | 0 | 0 | monetary | D | C | Payments for Repurchase of Common Stock | The cash outflow to reacquire common stock during the period. |
| Payments To Acquire Businesses Net Of Cash Acquired | us-gaap/2025 | 0 | 0 | monetary | D | C | Payments to Acquire Businesses, Net of Cash Acquired | The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase. |
| Payments To Acquire Marketable Securities | us-gaap/2025 | 0 | 0 | monetary | D | C | Payments to Acquire Marketable Securities | Amount of cash outflow for purchase of marketable security. |
| Other Research And Development Expense Refund | 0001792044-25-000018 | 1 | 0 | monetary | D | D | Other Research And Development Expense (Refund) | Other Research And Development Expense (Refund) |
| Increase Decrease In Accounts Payable Trade | us-gaap/2025 | 0 | 0 | monetary | D | D | Increase (Decrease) in Accounts Payable, Trade | Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services. |
| Operating Income Loss | us-gaap/2025 | 0 | 0 | monetary | D | C | Operating Income (Loss) | The net result for the period of deducting operating expenses from operating revenues. |
| Payments For Proceeds From Other Investing Activities | us-gaap/2025 | 0 | 0 | monetary | D | C | Payment for (Proceeds from) Other Investing Activity | Amount of cash (inflow) outflow from investing activity, classified as other. |
| Research And Development Expense | us-gaap/2025 | 0 | 0 | monetary | D | D | Research and Development Expense | Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. |
| Weighted Average Number Of Shares Outstanding Basic | us-gaap/2025 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Basic | Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. | |
| Accounts Receivable Net Current | us-gaap/2025 | 0 | 0 | monetary | I | D | Accounts Receivable, after Allowance for Credit Loss, Current | Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. |
| Increase Decrease In Accrued Income Taxes Payable | us-gaap/2025 | 0 | 0 | monetary | D | D | Increase (Decrease) in Income Taxes Payable | The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction. |
| Other Liabilities Noncurrent | us-gaap/2025 | 0 | 0 | monetary | I | C | Other Liabilities, Noncurrent | Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer. |
| Proceeds From Repayments Of Short Term Debt | us-gaap/2025 | 0 | 0 | monetary | D | D | Proceeds from (Repayments of) Short-Term Debt | The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer. |
| Changeinnoncashlitigationsettlementsnet | 0001792044-25-000018 | 1 | 0 | monetary | D | C | Change in noncash litigation settlements, net | Change in noncash litigation settlements, net |
| Payments To Acquire Property Plant And Equipment | us-gaap/2025 | 0 | 0 | monetary | D | C | Payments to Acquire Property, Plant, and Equipment | The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. |
| Common Stock Dividends Per Share Cash Paid | us-gaap/2025 | 0 | 0 | perShare | D | Common Stock, Dividends, Per Share, Cash Paid | Aggregate dividends paid during the period for each share of common stock outstanding. | |
| Gain Loss Related To Litigation Settlement | us-gaap/2025 | 0 | 0 | monetary | D | C | Gain (Loss) from Litigation Settlement | Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process. |
| Interest Expense | us-gaap/2025 | 0 | 0 | monetary | D | D | Interest Expense, Operating and Nonoperating | Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. |
| Revenue Not From Contract With Customer | us-gaap/2025 | 0 | 0 | monetary | D | C | Revenue Not from Contract with Customer | Amount of revenue that is not accounted for under Topic 606. |
| Stock Issued During Period Shares New Issues | us-gaap/2025 | 0 | 0 | shares | D | Stock Issued During Period, Shares, New Issues | Number of new stock issued during the period. | |
| Increase Decrease In Inventories | us-gaap/2025 | 0 | 0 | monetary | D | C | Increase (Decrease) in Inventories | The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. |
| Liabilities Current | us-gaap/2025 | 0 | 0 | monetary | I | C | Liabilities, Current | Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. |
| Net Cash Provided By Used In Financing Activities | us-gaap/2025 | 0 | 0 | monetary | D | D | Cash Provided by (Used in) Financing Activity, Including Discontinued Operation | Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit. |
| Dividends Common Stock Cash | us-gaap/2025 | 0 | 0 | monetary | D | D | Dividends, Common Stock, Cash | Amount of paid and unpaid common stock dividends declared with the form of settlement in cash. |
| Other Assets Noncurrent | us-gaap/2025 | 0 | 0 | monetary | I | D | Other Assets, Noncurrent | Amount of noncurrent assets classified as other. |
| Deferred Income Tax Expense Benefit | us-gaap/2025 | 0 | 0 | monetary | D | D | Deferred Income Tax Expense (Benefit) | Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. |
| Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax | us-gaap/2025 | 0 | 0 | monetary | D | C | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax | Amount, before tax and after adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. |
| Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Before Tax | us-gaap/2025 | 0 | 0 | monetary | D | C | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax | Amount, before tax and after reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness. |
| Restricted Stock Value Shares Issued Net Of Tax Withholdings | us-gaap/2025 | 0 | 0 | monetary | D | C | Restricted Stock, Value, Shares Issued Net of Tax Withholdings | Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation. |
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax | us-gaap/2025 | 0 | 0 | monetary | D | C | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax | Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. |
| Other Noncash Income Expense | us-gaap/2025 | 0 | 0 | monetary | D | C | Other Noncash Income (Expense) | Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other. |
| Proceeds From Divestiture Of Businesses | us-gaap/2025 | 0 | 0 | monetary | D | D | Proceeds from Divestiture of Businesses | The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period. |
| Proceeds From Sale And Maturity Of Marketable Securities | us-gaap/2025 | 0 | 0 | monetary | D | D | Proceeds from Sale and Maturity of Marketable Securities | The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period. |
| Proceeds From Sale Of Productive Assets | us-gaap/2025 | 0 | 0 | monetary | D | D | Proceeds from Sale of Productive Assets | The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets. |
| Shares Issued | us-gaap/2025 | 0 | 0 | shares | I | Shares, Issued | Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. | |
| Assets | us-gaap/2025 | 0 | 0 | monetary | I | D | Assets | Amount of asset recognized for present right to economic benefit. |
| Increase Decrease In Accounts Receivable | us-gaap/2025 | 0 | 0 | monetary | D | C | Increase (Decrease) in Accounts Receivable | The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. |
| Liabilities And Stockholders Equity | us-gaap/2025 | 0 | 0 | monetary | I | C | Liabilities and Equity | Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. |
| Other Nonoperating Income Expense | us-gaap/2025 | 0 | 0 | monetary | D | C | Other Nonoperating Income (Expense) | Amount of income (expense) related to nonoperating activities, classified as other. |
| Accumulated Other Comprehensive Income Loss Net Of Tax | us-gaap/2025 | 0 | 0 | monetary | I | C | Accumulated Other Comprehensive Income (Loss), Net of Tax | Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. |
| Adjustments Related To Tax Withholding For Share Based Compensation | us-gaap/2025 | 0 | 0 | monetary | D | D | Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation | Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement. |
| Goodwill | us-gaap/2025 | 0 | 0 | monetary | I | D | Goodwill | Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. |
| Other Comprehensive Income Loss Net Of Tax | us-gaap/2025 | 0 | 0 | monetary | D | C | Other Comprehensive Income (Loss), Net of Tax | Amount after tax and reclassification adjustments of other comprehensive income (loss). |
| Prepaid Expense And Other Assets Current | us-gaap/2025 | 0 | 0 | monetary | I | D | Prepaid Expense and Other Assets, Current | Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. |
| Proceeds From Refund Of In Process Research And Development | 0001792044-25-000018 | 1 | 0 | monetary | D | D | Proceeds From Refund Of In Process Research And Development | Proceeds From Refund Of In Process Research And Development |
| Stockholders Equity Parent Before Treasury Stock | 0001792044-25-000018 | 1 | 0 | monetary | I | C | Stockholders Equity Parent Before Treasury Stock | Total amount of stockholders' equity (deficit) items including stock value, paid in capital, retained earnings that are attributable to the parent company, excluding equity attributable to noncontrolling interests, and before deducting the carrying value of treasury stock. |
| Assets Current | us-gaap/2025 | 0 | 0 | monetary | I | D | Assets, Current | Amount of asset recognized for present right to economic benefit, classified as current. |
| Gross Profit | us-gaap/2025 | 0 | 0 | monetary | D | C | Gross Profit | Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. |
| Income Tax Expense Benefit | us-gaap/2025 | 0 | 0 | monetary | D | D | Income Tax Expense (Benefit) | Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. |
| Inventory Net | us-gaap/2025 | 0 | 0 | monetary | I | D | Inventory, Net | Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. |
| Revenues | us-gaap/2025 | 0 | 0 | monetary | D | C | Revenues | Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). |
| Liabilities | us-gaap/2025 | 0 | 0 | monetary | I | C | Liabilities | Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | us-gaap/2025 | 0 | 0 | monetary | I | C | Equity, Including Portion Attributable to Noncontrolling Interest | Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2025 | 0 | 0 | monetary | I | D | Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation | Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate. |
| Gain Loss On Sale Of Business | us-gaap/2025 | 0 | 0 | monetary | D | C | Gain (Loss) on Disposition of Business | Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant. |
| Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Tax | us-gaap/2025 | 0 | 0 | monetary | D | D | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax | Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan. |
| Payments To Minority Shareholders | us-gaap/2025 | 0 | 0 | monetary | D | C | Payments to Noncontrolling Interests | Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest. |
| Share Based Compensation | us-gaap/2025 | 0 | 0 | monetary | D | D | Share-Based Payment Arrangement, Noncash Expense | Amount of noncash expense for share-based payment arrangement. |
| Treasury Stock Common Shares | us-gaap/2025 | 0 | 0 | shares | I | Treasury Stock, Common, Shares | Number of previously issued common shares repurchased by the issuing entity and held in treasury. | |
| Treasury Stock Shares Acquired | us-gaap/2025 | 0 | 0 | shares | D | Treasury Stock, Shares, Acquired | Number of shares that have been repurchased during the period and are being held in treasury. | |
| Treasury Stock Value Acquired Cost Method | us-gaap/2025 | 0 | 0 | monetary | D | D | Treasury Stock, Value, Acquired, Cost Method | Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method. |
| Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2025 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Diluted | The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. | |
| Cost Of Goods And Services Sold | us-gaap/2025 | 0 | 0 | monetary | D | D | Cost of Product and Service Sold | The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. |
| Treasury Stock Value | us-gaap/2025 | 0 | 0 | monetary | I | D | Treasury Stock, Value | The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury. |
| Net Income Loss Available To Common Stockholders Basic | us-gaap/2025 | 0 | 0 | monetary | D | C | Net Income (Loss) Available to Common Stockholders, Basic | Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. |
| Payments Of Merger Related Costs Financing Activities | us-gaap/2025 | 0 | 0 | monetary | D | C | Payments of Merger Related Costs, Financing Activities | The cash outflow for financing costs associated with business combinations. |
| Proceeds From Payments For Other Financing Activities | us-gaap/2025 | 0 | 0 | monetary | D | D | Proceeds from (Payment for) Other Financing Activity | Amount of cash inflow (outflow) from financing activity, classified as other. |
| Net Cash Provided By Used In Operating Activities | us-gaap/2025 | 0 | 0 | monetary | D | Cash Provided by (Used in) Operating Activity, Including Discontinued Operation | Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity. | |
| Retained Earnings Accumulated Deficit | us-gaap/2025 | 0 | 0 | monetary | I | C | Retained Earnings (Accumulated Deficit) | Amount of accumulated undistributed earnings (deficit). |
| Common Stock Value | us-gaap/2025 | 0 | 0 | monetary | I | C | Common Stock, Value, Issued | Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. |
| Stock Issued During Period Value New Issues | us-gaap/2025 | 0 | 0 | monetary | D | C | Stock Issued During Period, Value, New Issues | Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. |
| Field Name | Field Description |
|---|---|
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| custom | 1 if tag is custom (version=adsh), 0 if it is standard. Note: This flag is technically redundant with the version and adsh columns. |
| abstract | 1 if the tag is not used to represent a numeric fact. |
| datatype | If abstract=1, then NULL, otherwise the data type (e.g., monetary) for the tag. |
| iord | If abstract=1, then NULL; otherwise, “I” if the value is a point-in time, or “D” if the value is a duration. |
| crdr | If datatype = monetary, then the tag’s natural accounting balance (debit or credit); if not defined, then NULL. |
| tlabel | If a standard tag, then the label text provided by the taxonomy, otherwise the text provided by the filer. A tag which had neither would have a NULL value here. |
| doc | The detailed definition for the tag. If a standard tag, then the text provided by the taxonomy, otherwise the text assigned by the filer. Some tags have neither, and this field is NULL. |
| adsh | report | line | stmt | inpth | rfile | tag | version | plabel | negating |
|---|---|---|---|---|---|---|---|---|---|
| 0001792044-25-000018 | 2 | 1 | IS | 0 | H | Revenue From Contract With Customer Excluding Assessed Tax | us-gaap/2025 | Net sales | 0 |
| 0001792044-25-000018 | 2 | 2 | IS | 0 | H | Revenue Not From Contract With Customer | us-gaap/2025 | Other revenues | 0 |
| 0001792044-25-000018 | 2 | 3 | IS | 0 | H | Revenues | us-gaap/2025 | Total revenues | 0 |
| 0001792044-25-000018 | 2 | 4 | IS | 0 | H | Cost Of Goods And Services Sold | us-gaap/2025 | Cost of sales | 0 |
| 0001792044-25-000018 | 2 | 5 | IS | 0 | H | Gross Profit | us-gaap/2025 | Gross profit | 0 |
| 0001792044-25-000018 | 2 | 7 | IS | 0 | H | Research And Development Expense | us-gaap/2025 | Research and development | 0 |
| 0001792044-25-000018 | 2 | 8 | IS | 0 | H | Other Research And Development Expense Refund | 0001792044-25-000018 | Acquired IPR&D | 0 |
| 0001792044-25-000018 | 2 | 9 | IS | 0 | H | Selling General And Administrative Expense | us-gaap/2025 | Selling, general and administrative | 0 |
| 0001792044-25-000018 | 2 | 10 | IS | 0 | H | Goodwill Impairment Loss | us-gaap/2025 | Impairment of goodwill | 0 |
| 0001792044-25-000018 | 2 | 11 | IS | 0 | H | Gain Loss Related To Litigation Settlement | us-gaap/2025 | Litigation settlements and other contingencies, net | 1 |
| 0001792044-25-000018 | 2 | 12 | IS | 0 | H | Operating Expenses | us-gaap/2025 | Total operating expenses | 0 |
| 0001792044-25-000018 | 2 | 13 | IS | 0 | H | Operating Income Loss | us-gaap/2025 | (Loss) earnings from operations | 0 |
| 0001792044-25-000018 | 2 | 14 | IS | 0 | H | Interest Expense | us-gaap/2025 | Interest expense | 0 |
| 0001792044-25-000018 | 2 | 15 | IS | 0 | H | Other Nonoperating Income Expense | us-gaap/2025 | Other expense (income), net | 1 |
| 0001792044-25-000018 | 2 | 16 | IS | 0 | H | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | us-gaap/2025 | (Loss) earnings before income taxes | 0 |
| 0001792044-25-000018 | 2 | 17 | IS | 0 | H | Income Tax Expense Benefit | us-gaap/2025 | Income tax (benefit) provision | 0 |
| 0001792044-25-000018 | 2 | 18 | IS | 0 | H | Net Income Loss Available To Common Stockholders Basic | us-gaap/2025 | Net (loss) earnings | 0 |
| 0001792044-25-000018 | 2 | 20 | IS | 0 | H | Earnings Per Share Basic | us-gaap/2025 | Basic (in USD per share) | 0 |
| 0001792044-25-000018 | 2 | 21 | IS | 0 | H | Earnings Per Share Diluted | us-gaap/2025 | Diluted (in USD per share) | 0 |
| 0001792044-25-000018 | 2 | 23 | IS | 0 | H | Weighted Average Number Of Shares Outstanding Basic | us-gaap/2025 | Basic (in shares) | 0 |
| 0001792044-25-000018 | 2 | 24 | IS | 0 | H | Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2025 | Diluted (in shares) | 0 |
| 0001792044-25-000018 | 3 | 7 | CI | 0 | H | Net Income Loss Available To Common Stockholders Basic | us-gaap/2025 | Net (loss) earnings attributable to Viatris Inc. common shareholders | 0 |
| 0001792044-25-000018 | 3 | 9 | CI | 0 | H | Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax | us-gaap/2025 | Foreign currency translation adjustment | 0 |
| 0001792044-25-000018 | 3 | 10 | CI | 0 | H | Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Tax | us-gaap/2025 | Change in unrecognized loss and prior service cost related to defined benefit plans | 1 |
| 0001792044-25-000018 | 3 | 11 | CI | 0 | H | Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Before Tax | us-gaap/2025 | Net unrecognized gain (loss) on derivatives | 0 |
| 0001792044-25-000018 | 3 | 12 | CI | 0 | H | Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax | us-gaap/2025 | Net unrealized gain (loss) on available-for-sale fixed income securities | 0 |
| 0001792044-25-000018 | 3 | 13 | CI | 0 | H | Other Comprehensive Income Loss Before Tax Portion Attributable To Parent | us-gaap/2025 | Other comprehensive earnings (loss), before tax | 0 |
| 0001792044-25-000018 | 3 | 14 | CI | 0 | H | Other Comprehensive Income Loss Tax | us-gaap/2025 | Income tax (benefit) provision | 0 |
| 0001792044-25-000018 | 3 | 15 | CI | 0 | H | Other Comprehensive Income Loss Net Of Tax | us-gaap/2025 | Other comprehensive earnings (loss), net of tax | 0 |
| 0001792044-25-000018 | 3 | 16 | CI | 0 | H | Comprehensive Income Net Of Tax | us-gaap/2025 | Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Total | 0 |
| 0001792044-25-000018 | 4 | 3 | BS | 0 | H | Cash And Cash Equivalents At Carrying Value | us-gaap/2025 | Cash and cash equivalents | 0 |
| 0001792044-25-000018 | 4 | 4 | BS | 0 | H | Accounts Receivable Net Current | us-gaap/2025 | Accounts receivable, net | 0 |
| 0001792044-25-000018 | 4 | 5 | BS | 0 | H | Inventory Net | us-gaap/2025 | Inventories | 0 |
| 0001792044-25-000018 | 4 | 6 | BS | 0 | H | Prepaid Expense And Other Assets Current | us-gaap/2025 | Prepaid expenses and other current assets | 0 |
| 0001792044-25-000018 | 4 | 7 | BS | 0 | H | Assets Current | us-gaap/2025 | Total current assets | 0 |
| 0001792044-25-000018 | 4 | 8 | BS | 0 | H | Property Plant And Equipment Net | us-gaap/2025 | Property, plant and equipment, net | 0 |
| 0001792044-25-000018 | 4 | 9 | BS | 0 | H | Intangible Assets Net Excluding Goodwill | us-gaap/2025 | Intangible assets, net | 0 |
| 0001792044-25-000018 | 4 | 10 | BS | 0 | H | Goodwill | us-gaap/2025 | Goodwill | 0 |
| 0001792044-25-000018 | 4 | 11 | BS | 0 | H | Deferred Income Tax Assets Net | us-gaap/2025 | Deferred income tax benefit | 0 |
| 0001792044-25-000018 | 4 | 12 | BS | 0 | H | Other Assets Noncurrent | us-gaap/2025 | Other assets | 0 |
| 0001792044-25-000018 | 4 | 13 | BS | 0 | H | Assets | us-gaap/2025 | Total assets | 0 |
| 0001792044-25-000018 | 4 | 17 | BS | 0 | H | Accounts Payable Trade Current | us-gaap/2025 | Accounts payable | 0 |
| 0001792044-25-000018 | 4 | 18 | BS | 0 | H | Accrued Income Taxes Current | us-gaap/2025 | Income taxes payable | 0 |
| 0001792044-25-000018 | 4 | 19 | BS | 0 | H | Long Term Debt Current | us-gaap/2025 | Current portion of long-term debt and other long-term obligations | 0 |
| 0001792044-25-000018 | 4 | 20 | BS | 0 | H | Other Liabilities Current | us-gaap/2025 | Other current liabilities | 0 |
| 0001792044-25-000018 | 4 | 21 | BS | 0 | H | Liabilities Current | us-gaap/2025 | Total current liabilities | 0 |
| 0001792044-25-000018 | 4 | 22 | BS | 0 | H | Long Term Debt Noncurrent | us-gaap/2025 | Long-term debt | 0 |
| 0001792044-25-000018 | 4 | 23 | BS | 0 | H | Deferred Income Tax Liabilities Net | us-gaap/2025 | Deferred income tax liability | 0 |
| 0001792044-25-000018 | 4 | 24 | BS | 0 | H | Other Liabilities Noncurrent | us-gaap/2025 | Other long-term obligations | 0 |
| 0001792044-25-000018 | 4 | 25 | BS | 0 | H | Liabilities | us-gaap/2025 | Total liabilities | 0 |
| 0001792044-25-000018 | 4 | 28 | BS | 0 | H | Common Stock Value | us-gaap/2025 | Common stock: $0.01 par value, 3,000,000,000 shares authorized; shares issued: 1,244,908,128 and 1,234,131,491 as of March 31, 2025 and December 31, 2024 | 0 |
| 0001792044-25-000018 | 4 | 29 | BS | 0 | H | Additional Paid In Capital | us-gaap/2025 | Additional paid-in capital | 0 |
| 0001792044-25-000018 | 4 | 30 | BS | 0 | H | Retained Earnings Accumulated Deficit | us-gaap/2025 | Retained earnings | 0 |
| 0001792044-25-000018 | 4 | 31 | BS | 0 | H | Accumulated Other Comprehensive Income Loss Net Of Tax | us-gaap/2025 | Accumulated other comprehensive loss | 0 |
| 0001792044-25-000018 | 4 | 32 | BS | 0 | H | Stockholders Equity Parent Before Treasury Stock | 0001792044-25-000018 | Total Viatris Inc. equity, before treasury stock | 0 |
| 0001792044-25-000018 | 4 | 33 | BS | 0 | H | Treasury Stock Value | us-gaap/2025 | Less: Treasury stock at cost | 0 |
| 0001792044-25-000018 | 4 | 34 | BS | 0 | H | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | us-gaap/2025 | Total equity | 0 |
| 0001792044-25-000018 | 4 | 35 | BS | 0 | H | Liabilities And Stockholders Equity | us-gaap/2025 | Total liabilities and equity | 0 |
| 0001792044-25-000018 | 5 | 7 | BS | 1 | H | Common Stock Shares Authorized | us-gaap/2025 | Ordinary shares, shares authorized | 0 |
| 0001792044-25-000018 | 5 | 8 | BS | 1 | H | Treasury Stock Common Shares | us-gaap/2025 | Treasury stock, shares | 0 |
| 0001792044-25-000018 | 6 | 11 | EQ | 0 | H | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | us-gaap/2025 | Balance | 0 |
| 0001792044-25-000018 | 6 | 12 | EQ | 0 | H | Shares Issued | us-gaap/2025 | Balance (in shares) | 0 |
| 0001792044-25-000018 | 6 | 13 | EQ | 0 | H | Treasury Stock Value | us-gaap/2025 | Treasury Stock, Value | 1 |
| 0001792044-25-000018 | 6 | 14 | EQ | 0 | H | Treasury Stock Common Shares | us-gaap/2025 | Treasury Stock, Common, Shares | 0 |
| 0001792044-25-000018 | 6 | 15 | EQ | 0 | H | Net Income Loss Available To Common Stockholders Basic | us-gaap/2025 | Net earnings (loss) | 0 |
| 0001792044-25-000018 | 6 | 16 | EQ | 0 | H | Other Comprehensive Income Loss Net Of Tax | us-gaap/2025 | Other comprehensive earnings, net of tax | 0 |
| 0001792044-25-000018 | 6 | 17 | EQ | 0 | H | Stock Issued During Period Value Stock Options Exercised Net Of Shares Tendered For Payment | 0001792044-25-000018 | Issuance of restricted stock, net of shares withheld (in shares) | 0 |
| 0001792044-25-000018 | 6 | 18 | EQ | 0 | H | Restricted Stock Value Shares Issued Net Of Tax Withholdings | us-gaap/2025 | Issuance of restricted stock and stock options exercised, net | 0 |
| 0001792044-25-000018 | 6 | 19 | EQ | 0 | H | Adjustments Related To Tax Withholding For Share Based Compensation | us-gaap/2025 | Taxes related to the net share settlement of equity awards | 1 |
| 0001792044-25-000018 | 6 | 20 | EQ | 0 | H | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | us-gaap/2025 | Share-based compensation expense | 0 |
| 0001792044-25-000018 | 6 | 21 | EQ | 0 | H | Treasury Stock Value Acquired Cost Method | us-gaap/2025 | Common stock repurchase | 1 |
| 0001792044-25-000018 | 6 | 22 | EQ | 0 | H | Payments For Repurchase Of Common Stock | us-gaap/2025 | Payments for Repurchase of Common Stock | 0 |
| 0001792044-25-000018 | 6 | 23 | EQ | 0 | H | Stock Issued During Period Shares New Issues | us-gaap/2025 | Stock Issued During Period, Shares, New Issues | 0 |
| 0001792044-25-000018 | 6 | 24 | EQ | 0 | H | Treasury Stock Shares Acquired | us-gaap/2025 | Treasury Stock, Shares, Acquired | 0 |
| 0001792044-25-000018 | 6 | 25 | EQ | 0 | H | Stock Issued During Period Value New Issues | us-gaap/2025 | Stock Issued During Period, Value, New Issues | 0 |
| 0001792044-25-000018 | 6 | 26 | EQ | 0 | H | Common Stock Dividends Per Share Cash Paid | us-gaap/2025 | Dividends paid (in dollars per share) | 0 |
| 0001792044-25-000018 | 6 | 27 | EQ | 0 | H | Dividends Common Stock Cash | us-gaap/2025 | Cash dividends declared, $0.12 per common share | 1 |
| 0001792044-25-000018 | 6 | 28 | EQ | 0 | H | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | us-gaap/2025 | Balance | 0 |
| 0001792044-25-000018 | 6 | 29 | EQ | 0 | H | Shares Issued | us-gaap/2025 | Balance (in shares) | 0 |
| 0001792044-25-000018 | 7 | 2 | CF | 0 | H | Net Income Loss Available To Common Stockholders Basic | us-gaap/2025 | Net (loss) earnings attributable to Viatris Inc. common shareholders | 0 |
| 0001792044-25-000018 | 7 | 4 | CF | 0 | H | Depreciation Depletion And Amortization | us-gaap/2025 | Depreciation and amortization | 0 |
| 0001792044-25-000018 | 7 | 5 | CF | 0 | H | Share Based Compensation | us-gaap/2025 | Share-based compensation expense | 0 |
| 0001792044-25-000018 | 7 | 6 | CF | 0 | H | Deferred Income Tax Expense Benefit | us-gaap/2025 | Deferred income tax benefit | 0 |
| 0001792044-25-000018 | 7 | 7 | CF | 0 | H | Gain Loss On Sale Of Business | us-gaap/2025 | Loss (gain) on disposal of business | 1 |
| 0001792044-25-000018 | 7 | 8 | CF | 0 | H | Payments To Acquire In Process Research And Development Other | 0001792044-25-000018 | Acquired IPR&D | 1 |
| 0001792044-25-000018 | 7 | 9 | CF | 0 | H | Goodwill Impairment Loss | us-gaap/2025 | Impairment of goodwill | 0 |
| 0001792044-25-000018 | 7 | 10 | CF | 0 | H | Other Noncash Income Expense | us-gaap/2025 | Other non-cash items | 1 |
| 0001792044-25-000018 | 7 | 11 | CF | 0 | H | Changeinnoncashlitigationsettlementsnet | 0001792044-25-000018 | Litigation settlements and other contingencies, net | 1 |
| 0001792044-25-000018 | 7 | 13 | CF | 0 | H | Increase Decrease In Accounts Receivable | us-gaap/2025 | Accounts receivable | 1 |
| 0001792044-25-000018 | 7 | 14 | CF | 0 | H | Increase Decrease In Inventories | us-gaap/2025 | Inventories | 1 |
| 0001792044-25-000018 | 7 | 15 | CF | 0 | H | Increase Decrease In Accounts Payable Trade | us-gaap/2025 | Accounts payable | 0 |
| 0001792044-25-000018 | 7 | 16 | CF | 0 | H | Increase Decrease In Accrued Income Taxes Payable | us-gaap/2025 | Income taxes | 0 |
| 0001792044-25-000018 | 7 | 17 | CF | 0 | H | Increase Decrease In Other Operating Capital Net | us-gaap/2025 | Other operating assets and liabilities, net | 1 |
| 0001792044-25-000018 | 7 | 18 | CF | 0 | H | Net Cash Provided By Used In Operating Activities | us-gaap/2025 | Net cash provided by operating activities | 0 |
| 0001792044-25-000018 | 7 | 20 | CF | 0 | H | Payments To Acquire Businesses Net Of Cash Acquired | us-gaap/2025 | Cash paid for acquisitions, net of cash acquired | 1 |
| 0001792044-25-000018 | 7 | 21 | CF | 0 | H | Payments To Acquire Property Plant And Equipment | us-gaap/2025 | Capital expenditures | 1 |
| 0001792044-25-000018 | 7 | 22 | CF | 0 | H | Payments To Acquire Marketable Securities | us-gaap/2025 | Purchase of marketable securities | 1 |
| 0001792044-25-000018 | 7 | 23 | CF | 0 | H | Proceeds From Sale And Maturity Of Marketable Securities | us-gaap/2025 | Proceeds from the sale of marketable securities | 0 |
| 0001792044-25-000018 | 7 | 24 | CF | 0 | H | Payments For Proceeds From Other Investing Activities | us-gaap/2025 | Payments for product rights and other, net | 1 |
| 0001792044-25-000018 | 7 | 25 | CF | 0 | H | Proceeds From Refund Of In Process Research And Development | 0001792044-25-000018 | (Purchases) refunds of IPR&D | 0 |
| 0001792044-25-000018 | 7 | 26 | CF | 0 | H | Proceeds From Divestiture Of Businesses | us-gaap/2025 | Proceeds from sale of assets and subsidiaries | 0 |
| 0001792044-25-000018 | 7 | 27 | CF | 0 | H | Proceeds From Sale Of Productive Assets | us-gaap/2025 | Proceeds from the sale of property, plant and equipment | 0 |
| 0001792044-25-000018 | 7 | 28 | CF | 0 | H | Net Cash Provided By Used In Investing Activities | us-gaap/2025 | Net cash used in investing activities | 0 |
| 0001792044-25-000018 | 7 | 30 | CF | 0 | H | Payments For Repurchase Of Common Stock | us-gaap/2025 | Purchase of common stock | 1 |
| 0001792044-25-000018 | 7 | 31 | CF | 0 | H | Proceeds From Repayments Of Short Term Debt | us-gaap/2025 | Change in short-term borrowings, net | 0 |
| 0001792044-25-000018 | 7 | 32 | CF | 0 | H | Payments Related To Tax Withholding For Share Based Compensation | us-gaap/2025 | Taxes paid related to net share settlement of equity awards | 1 |
| 0001792044-25-000018 | 7 | 33 | CF | 0 | H | Payments Of Merger Related Costs Financing Activities | us-gaap/2025 | Contingent consideration payments | 1 |
| 0001792044-25-000018 | 7 | 34 | CF | 0 | H | Payments To Minority Shareholders | us-gaap/2025 | Cash dividends paid | 1 |
| 0001792044-25-000018 | 7 | 35 | CF | 0 | H | Proceeds From Issuance Of Common Stock | us-gaap/2025 | Issuance of common stock | 0 |
| 0001792044-25-000018 | 7 | 36 | CF | 0 | H | Proceeds From Payments For Other Financing Activities | us-gaap/2025 | Other items, net | 0 |
| 0001792044-25-000018 | 7 | 37 | CF | 0 | H | Net Cash Provided By Used In Financing Activities | us-gaap/2025 | Net cash used in financing activities | 0 |
| 0001792044-25-000018 | 7 | 38 | CF | 0 | H | Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2025 | Effect on cash of changes in exchange rates | 0 |
| 0001792044-25-000018 | 7 | 39 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2025 | Net increase in cash, cash equivalents and restricted cash | 0 |
| 0001792044-25-000018 | 7 | 40 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2025 | Cash, cash equivalents and restricted cash beginning of period | 0 |
| 0001792044-25-000018 | 7 | 41 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2025 | Cash, cash equivalents and restricted cash end of period | 0 |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| report | Represents the report grouping. This field corresponds to the statement (stmt) field, which indicates the type of statement. The numeric value refers to the “R file” as posted on the EDGAR Web site. |
| line | Represents the tag’s presentation line order for a given report. Together with the statement and report field, presentation location, order and grouping can be derived. |
| stmt | The financial statement location to which the value of the “report” field pertains. |
| inpth | Value was presented “parenthetically” instead of in columns within the financial statements. For example: Receivables (net of allowance for bad debts of $200 in 2012) $700. |
| rfile | The type of interactive data file rendered on the EDGAR web site, H = .htm file, X = .xml file. |
| tag | The tag chosen by the filer for this line item. |
| version | The taxonomy identifier if the tag is a standard tag, otherwise adsh. |
| plabel | The text presented on the line item, also known as a “preferred” label. |
| negating | Flag to indicate whether the plabel is negating. |